GeoVax Labs’ (GOVX) “Outperform” Rating Reiterated at Noble Financial

Noble Financial restated their outperform rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research report sent to investors on Tuesday,Benzinga reports.

Other analysts have also recently issued research reports about the stock. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, GeoVax Labs currently has an average rating of “Hold” and a consensus price target of $150.00.

GeoVax Labs Price Performance

Shares of NASDAQ GOVX opened at $0.38 on Tuesday. The stock’s 50-day moving average is $0.70 and its two-hundred day moving average is $1.25. GeoVax Labs has a 1-year low of $0.38 and a 1-year high of $17.50. The company has a market cap of $2.82 million, a price-to-earnings ratio of -0.03 and a beta of 3.66.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Monday, July 27th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.16) by $1.19. Equities research analysts anticipate that GeoVax Labs will post -4.94 earnings per share for the current fiscal year.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.